Long-term outcome and predictors of long-term disease activity in natalizumab-treated patients with multiple sclerosis: real life data from the Austrian MS Treatment Registry

被引：0
作者：
Michael Guger
Christian Enzinger
Fritz Leutmezer
Franziska Di Pauli
Jörg Kraus
Stefan Kalcher
Erich Kvas
Thomas Berger
机构：
[1] Kepler University Hospital GmbH,Clinic for Neurology 2, Med Campus III
[2] Johannes Kepler University Linz,Medical Faculty
[3] Medical University of Graz,Department of Neurology
[4] Medical University of Vienna,Department of Neurology
[5] Medical University of Innsbruck,Clinical Department of Neurology
[6] Paracelsus Medical University and Salzburger Landeskliniken,Department of Laboratory Medicine
[7] Heinrich-Heine-University,Department of Neurology, Medical Faculty
[8] Hermesoft,undefined
[9] Data management,undefined
[10] Hermesoft,undefined
[11] Statistics,undefined
来源：
Journal of Neurology | 2021年 / 268卷
关键词：
Disability progression; Long-term; Multiple sclerosis; Natalizumab; Predictor;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：4303 / 4310
页数：7
相关论文
共 50 条
  • [21] Survival: the ultimate long-term outcome in multiple sclerosis
    Giovannoni, Gavin
    BRAIN, 2019, 142 : 1166 - 1167
  • [22] Long-term management of natalizumab discontinuation in a large monocentric cohort of multiple sclerosis patients
    Sangalli, Francesca
    Moiola, Lucia
    Ferre, Laura
    Radaelli, Marta
    Barcella, Valeria
    Rodegher, Mariaemma
    Colombo, Bruno
    Boneschi, Filippo Martinelli
    Martinelli, Vittorio
    Comi, Giancarlo
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2014, 3 (04) : 520 - 526
  • [23] Long-Term Follow-Up of Pediatric Patients Treated with Mitoxantrone for Multiple Sclerosis
    Kornek, B.
    Bernert, G.
    Rostasy, K.
    Mlczoch, E.
    Feucht, M.
    Prayer, D.
    Vass, K.
    Seidl, R.
    NEUROPEDIATRICS, 2011, 42 (01) : 7 - 12
  • [24] Early Clinical Predictors of Long-term Disability Progression in Patients with Multiple Sclerosis
    Ignatova, Valentina Georgieva
    Todorova, Lyudmila Pavlova
    Haralanov, Lyubomir Haralanov
    Vassilev, Peter M.
    INDIAN JOURNAL OF MEDICAL SPECIALITIES, 2024, 15 (01) : 48 - 52
  • [25] Long-term comparative analysis of no evidence of disease activity (NEDA-3) status between multiple sclerosis patients treated with natalizumab and fingolimod for up to 4 years
    Tommaso Guerra
    Francesca Caputo
    Bianca Orlando
    Damiano Paolicelli
    Maria Trojano
    Pietro Iaffaldano
    Neurological Sciences, 2021, 42 : 4647 - 4655
  • [26] Long-term comparative analysis of no evidence of disease activity (NEDA-3) status between multiple sclerosis patients treated with natalizumab and fingolimod for up to 4 years
    Guerra, Tommaso
    Caputo, Francesca
    Orlando, Bianca
    Paolicelli, Damiano
    Trojano, Maria
    Iaffaldano, Pietro
    NEUROLOGICAL SCIENCES, 2021, 42 (11) : 4647 - 4655
  • [27] Long-term treatment of multiple sclerosis with IgG immunotherapy
    Schuller, E
    Lambin, P
    Deloche, G
    PATHOLOGIE BIOLOGIE, 1996, 44 (08): : 710 - 715
  • [28] Long-term effectiveness in patients previously treated with cladribine tablets: a real-world analysis of the Italian multiple sclerosis registry (CLARINET-MS)
    Patti, Francesco
    Visconti, Andrea
    Capacchione, Antonio
    Roy, Sanjeev
    Trojano, Maria
    THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, 2020, 13
  • [29] Predictors of freedom from disease activity in natalizumab treated-patients with multiple sclerosis
    Prosperini, Luca
    Gianni, Costanza
    Barletta, Valeria
    Mancinelli, Chiara
    Fubelli, Federica
    Borriello, Giovanna
    Pozzilli, Carlo
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2012, 323 (1-2) : 104 - 112
  • [30] Long-term emotional state of multiple sclerosis patients treated with interferon beta
    Porcel, J.
    Rio, J.
    Sánchez-Betancourt, A.
    Arevalo, M. J.
    Tintore, M.
    Tellez, N.
    Borras, C.
    Nos, C.
    Montalban, X.
    MULTIPLE SCLEROSIS JOURNAL, 2006, 12 (06) : 802 - 807
12345